Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 1.00 |
| ▸ | BCR | P11274 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936260 | 1.00 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL29438984 | 1.00 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL25735737 | 0.92 | ABL1 (0.85) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL924853 | 0.90 | ABL1 (0.82) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL10013582 | 0.89 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3399317 | 0.89 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL12942835 | 0.88 | ABL1 (0.88) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL13771172 | 0.88 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL25639124 | 0.86 | ABL1 (0.82) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3900043 | 0.84 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4313007-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | Lyfe CHNG, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-3700516-B1 | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LTD (VG) | 2024-01-24 | — | — | EP | disclosed |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023114759-A2 | ABL INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230026731-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | LCT TECHNOLOGIES LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-2229217-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2010-09-22 | — | — | EP | disclosed |
| US-20100216828-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | IRM LLC (BM) | 2010-08-26 | — | — | US | disclosed |
| EP-2187967-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009091476-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091476-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2009-07-23 | — | — | WO | disclosed |
| EP-1613595-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009026075-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | IRM LLC (BM) | 2009-02-26 | — | — | WO | disclosed |
| EP-1613595-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-11 | — | — | EP | disclosed |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2004089286-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026731-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | HTR7, HTR6, PNMT | ABL1 2050/4885BCR 2791/4885KDM4E 1479/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | ABL1 1463/4885BCR 904/4885KDM4E 1037/4885 |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | ABL1 1/4885BCR 4/4885KDM4E 395/4885 |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | ABL1 1/4885BCR 4/4885KDM4E 395/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | ABL1 1917/4885BCR 1873/4885KDM4E 2788/4885 |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | ABL1, BCR, PDGFRA | ABL1 1/4885BCR 2/4885KDM4E 1310/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | ABL1 31/4885BCR 80/4885KDM4E 2301/4885 |
| US-20100216828-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS | ABL1, KIT, SRC | ABL1 1/4885BCR 4/4885KDM4E 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.